Dinaciclib, also known as SCH-727965, is an experimental small-molecule drug that is currently being investigated as a potential treatment for various forms of cancer. This article will provide an overview of Dinaciclib, including its chemical properties, health benefits, potential effects, mechanism of action, safety, side effects, and dosing information.
Chemical Properties: Chemical name: (S)-1-(4-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(1-(2-hydroxyethyl)indol-3-yl)urea Molecular formula: C24H28N6O4 Formula weight: 464.52 g/mol CAS No: 779353-01-4
Top ten Google Keywords:
Synonyms: DINACICLIB SCH 727965 SCH727965 SCH-727965A 779353-01-4 1-(4-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(1-(2-hydroxyethyl)indol-3-yl)urea
Health Benefits: Dinaciclib is a promising anticancer drug that has shown great potential in treating various types of cancer, including lung cancer, breast cancer, and hematologic malignancies. Dinaciclib works by inhibiting cyclin-dependent kinases (CDKs), which are crucial regulators of the cell cycle. By blocking CDKs, Dinaciclib stops tumors from growing, and actively induces tumor cell death.
Potential Effects: Dinaciclib has shown significant efficacy in preclinical trials, and several clinical trials are currently underway to investigate its efficacy in different cancers such as breast or lung cancers. In a Phase I clinical trial, Dinaciclib was well-tolerated and showed promising clinical activity in patients with relapsed/non-refractory leukemia.
Product Mechanism: Dinaciclib works by inhibiting various CDKs, which are key enzymes that regulate the cell cycle progression in various cell types. Dinaciclib targets the CDK1, CDK2, CDK5, and CDK9 enzymes and is known as a broad-spectrum CDK inhibitor. By exploiting the cell cycle checkpoint control mechanism, Dinaciclib triggers apoptosis or programmed cell death of cancer cells.
Safety: Dinaciclib has undergone extensive safety testing in preclinical trials and several phases of clinical trials to determine its safety and tolerability profile. However, Dinaciclib induces cytotoxicity and can cause some side effects like nausea, vomiting, fatigue, or myelosuppression.
Side Effects: Dinaciclib can cause some side effects, including:
Dosing Information: The recommended dosage of Dinaciclib varies depending on the patient's condition, weight, and other factors. However, typical dosing regimens involve intravenous administration of Dinaciclib at 9-50 mg/m² every 3-4 weeks.
Conclusion: Dinaciclib is a promising anticancer drug that shows significant potential in treating various cancer types. Dinaciclib works by inhibiting crucial enzymes responsible for the cell cycle progression of cancer cells, inducing apoptosis, and ultimately killing the tumor cells. While further investigation is still needed in clinical trials, this drug has demonstrated to be a promising treatment option for cancer. Nevertheless, individual response and adverse reaction from this compound may differ depending on the patient's condition, and it is a physician's role to determine the appropriate dosage level and monitor their patient carefully during the administration of Dinaciclib.
